NetworkNewsBreaks – Delic Holdings Corp. (CSE: D
Post# of 135
(Total Views: 173)
Posted On: 07/20/2022 4:44:10 PM
NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Celebrates Third Recognition of Delic Labs’ Dr. Markus Roggen to Cannabis Scientist Power List
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, was named to the Cannabis Scientist Power List for the third consecutive year. Due to his commitment to creating a body of work on cannabis research that will have a positive, lasting effect on the industry, Dr. Roggen is consistently recognized as one of the most influential figures in the processing professionals category. Under Dr. Roggen’s leadership, Delic Labs will transfer its cannabis sector expertise and experience to position in psychedelic research and safety testing. The lab has secured Health Canada 56 exemptions for chemistry analytics on psilocybin mushrooms and has received psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. In addition, the lab intends to perform research and tests on a host of compounds outside of psychedelic mushrooms, including MDMA and LSD. Within the next months, Delic Labs expects to receive a dealer’s license with the intent of commercializing psilocybin research and associated intellectual property (“IP”) for medical and research purposes.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, was named to the Cannabis Scientist Power List for the third consecutive year. Due to his commitment to creating a body of work on cannabis research that will have a positive, lasting effect on the industry, Dr. Roggen is consistently recognized as one of the most influential figures in the processing professionals category. Under Dr. Roggen’s leadership, Delic Labs will transfer its cannabis sector expertise and experience to position in psychedelic research and safety testing. The lab has secured Health Canada 56 exemptions for chemistry analytics on psilocybin mushrooms and has received psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. In addition, the lab intends to perform research and tests on a host of compounds outside of psychedelic mushrooms, including MDMA and LSD. Within the next months, Delic Labs expects to receive a dealer’s license with the intent of commercializing psilocybin research and associated intellectual property (“IP”) for medical and research purposes.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)